IntelGenx Technologies Corp. announced various changes to its management team. Following the planned retirement of its founder and CEO, Horst G. Zerbe, PhD, the new executive leadership team is designed to support its continued global growth as a leading CDMO for oral films and transdermal products, and in particular, to further prepare it for the potential commercialization of RIZAFILM VersaFilm, a proprietary oral thin film formulation of rizatriptan benzoate (active ingredient in Merck & Co.'s Maxalt®), and Buprenorphine Buccal Film, a generic version of Belbuca® (buprenorphine buccal film), in the United States.

The company announced Dwight Gorham has been appointed as Chief Executive Officer, effective immediately. He succeeds Horst G. Zerbe, who has retired from his position as CEO, but will continue to serve as Chairman of IntelGenx's Board of Directors. Mr. Gorham has an accomplished history of senior leadership success in the life sciences industry.

In an executive management career spanning more than three decades, he most recently served as President and CEO of Pillar 5 Pharma Inc. Before joining Pillar 5 in 2015, he served as Senior Vice President and General Manager Global Operations of Pharmascience Inc. Prior to that, he held a variety of senior roles, including: President and CEO at Accucaps Industries Ltd; a variety of management assignments at the Burroughs Wellcome & Co. facility in Montreal, Quebec; President (Founding) of Draxis Pharma Inc.; General Manager of Baker Cummings Ltd.; and Director of Operations at the Canadian arm of Glaxo plc (now GSK plc).